Trial Profile

Efficacy and safety of Anlotinib plus Epirubicin civ followed by Anlotinib sequential therapy in the first-line chemotherapy for advanced soft tissue sarcoma (STS): A single-arm phase 2 clinical trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Epirubicin (Primary)
Indications Dermatofibrosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
Focus Therapeutic Use

13 Oct 2022 Results published in the Clinical Cancer Research
22 Jul 2021 Status changed from not yet recruiting to completed, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com